9-O-Feruloyl-5,5'-dimethoxylariciresinolCAS# 166322-14-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 166322-14-1 | SDF | Download SDF |
| PubChem ID | 44448269 | Appearance | Powder |
| Formula | C32H36O11 | M.Wt | 596.6 |
| Type of Compound | Lignans | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(2S,3R,4R)-2-(4-hydroxy-3,5-dimethoxyphenyl)-4-[(4-hydroxy-3,5-dimethoxyphenyl)methyl]oxolan-3-yl]methyl (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate | ||
| SMILES | COC1=CC(=CC(=C1O)OC)CC2COC(C2COC(=O)C=CC3=CC(=C(C=C3)O)OC)C4=CC(=C(C(=C4)OC)O)OC | ||
| Standard InChIKey | NTYDMYPTASSNQW-XMFFLOPHSA-N | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. (+)-9'-O-trans-Feruloyl-5,5'-dimethoxylariciresinol shows cytotoxicity against a small panel of human tumor cell lines, with ED50 values of 9.86 to approximately 12.68 microg/ml. 2. (+)-9'-O-trans-feruloyl-5,5'-dimethoxylariciresinol can inhibit release of histamine from mast cells, it may have anti-allergic inflammatory effect. |
| Targets | TNF-α | IL Receptor |
9-O-Feruloyl-5,5'-dimethoxylariciresinol Dilution Calculator
9-O-Feruloyl-5,5'-dimethoxylariciresinol Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6762 mL | 8.3808 mL | 16.7616 mL | 33.5233 mL | 41.9041 mL |
| 5 mM | 0.3352 mL | 1.6762 mL | 3.3523 mL | 6.7047 mL | 8.3808 mL |
| 10 mM | 0.1676 mL | 0.8381 mL | 1.6762 mL | 3.3523 mL | 4.1904 mL |
| 50 mM | 0.0335 mL | 0.1676 mL | 0.3352 mL | 0.6705 mL | 0.8381 mL |
| 100 mM | 0.0168 mL | 0.0838 mL | 0.1676 mL | 0.3352 mL | 0.419 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Taberdivarine H
Catalog No.:BCN6958
CAS No.:1662688-34-7
- Argentinine
Catalog No.:BCN3987
CAS No.:16625-57-3
- Bathophenanthroline
Catalog No.:BCC8840
CAS No.:1662-01-7
- CCT251545
Catalog No.:BCC6487
CAS No.:1661839-45-7
- Ginkgolic acid C15:0
Catalog No.:BCN2483
CAS No.:16611-84-0
- 3,4-O-dimethylcedrusin
Catalog No.:BCN8211
CAS No.:166021-14-3
- Cyclogrifolin
Catalog No.:BCN7547
CAS No.:1660156-04-6
- Z-Thr-OBzl
Catalog No.:BCC2737
CAS No.:16597-50-5
- (-)-Tetramisole
Catalog No.:BCC4670
CAS No.:16595-80-5
- Calystegine A5
Catalog No.:BCN1887
CAS No.:165905-26-0
- Naltrexone
Catalog No.:BCC1783
CAS No.:16590-41-3
- 1-Hydroxy-N-methylacridone
Catalog No.:BCN7551
CAS No.:16584-54-6
- m-Nitrohydrocinnamic acid
Catalog No.:BCC9048
CAS No.:1664-57-9
- 1H-Pyrido[3,4-b]indole-1,3 4(2H,9H)-trione
Catalog No.:BCN7913
CAS No.:16641-79-5
- p-Nitrohydrocinnamic acid
Catalog No.:BCC9124
CAS No.:16642-79-8
- trans-4-(Trifluoromethyl)cinnamic acid
Catalog No.:BCN1534
CAS No.:16642-92-5
- Metaxalone
Catalog No.:BCC5223
CAS No.:1665-48-1
- Avasimibe
Catalog No.:BCC2274
CAS No.:166518-60-1
- H-Tyr(Bzl)-OH
Catalog No.:BCC3130
CAS No.:16652-64-5
- H-Pro-OBzl.HCl
Catalog No.:BCC3021
CAS No.:16652-71-4
- H-Val-OBzl.TosOH
Catalog No.:BCC3140
CAS No.:16652-76-9
- Eurycarpin A
Catalog No.:BCN4693
CAS No.:166547-20-2
- Ramelteon
Catalog No.:BCN2183
CAS No.:196597-26-9
- Anidulafungin
Catalog No.:BCC4233
CAS No.:166663-25-8
Reversal of multidrug resistance by 5,5'-dimethoxylariciresinol-4-O-beta-D-glucoside in doxorubicin-resistant human leukemia K562/DOX.[Pubmed:24347768]
Indian J Pharmacol. 2013 Nov-Dec;45(6):597-602.
OBJECTIVE: The objective of this study was to investigate the reversal effects of 5,5'-dimethoxylariciresinol-4'-O-beta-D-glucoside (DMAG) extracted from traditional Chinese medicines Mahonia on multidrug resistance (MDR) of human leukemia cells to chemotherapeutic agents. MATERIALS AND METHODS: MTT(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to determine the effect of DMAG on doxorubicin sensitivity to K562/DOX cells. Propidium iodide /Hoechst 33342 double staining assay was used to investigate the effect of DMAG on doxorubicin-induced cellular apoptosis. Intracellular accumulation of doxorubicin and rhodamine 123 assay were performed to evaluate the effect of DMAG on drugs efflux activity of P-glycoprotein. RESULTS: DMAG significantly enhanced the doxorubicin cytotoxicity to K562/DOX cells. In the presence of 1.0 muM of DMAG, the IC50 of doxorubicin decreased from 34.93 +/- 1.37 muM to 12.51 +/- 1.28 muM. DMAG of 1.0 muM significantly enhanced doxorubicin-induced cell apoptosis in K562/DOX cells and the enhancement was time-dependent. A significant increase in accumulation of doxorubicin in the presence of DMAG was observed. After treatment of the K562/DOX cells for 1 h with 15.0 muM doxorubicin alone, the fluorescence intensity was 33093.12. With the addition of 1.0 muM of DMAG, the fluorescence intensity of doxorubicin was 2.3-fold higher. A significant increase of accumulation of rhodamine 123 in the presence of DMAG was also observed. With the addition of 1.0 muM of DMAG, the fluorescence intensity was increased by 49.11% compared with rhodamine 123 alone. CONCLUSION: DMAG was shown to effectively enhance chemosensitivity of resistant cells, which makes it might be a suitable candidate for potential MDR-reversing agents.
